Lamivudine (Centaur Pharmaceuticals Private Limited)
Welcome to the PulseAid listing for the Lamivudine drug offered from Centaur Pharmaceuticals Private Limited. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Centaur Pharmaceuticals Private Limited |
NON-PROPRIETARY NAME: | Lamivudine |
SUBSTANCE NAME: | LAMIVUDINE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET |
MARKETING CATEGORY NAME: | ANDA |
START MARKETING DATE: | 2017-06-22 |
END MARKETING DATE: | 0000-00-00 |
Lamivudine HUMAN PRESCRIPTION DRUG Details:
Item Description | Lamivudine from Centaur Pharmaceuticals Private Limited |
LABELER NAME: | Centaur Pharmaceuticals Private Limited |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 150(mg/1) |
START MARKETING DATE: | 2017-06-22 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 64330-001_3d12167b-8a38-4ebe-820a-a69e0a51d504 |
PRODUCT NDC: | 64330-001 |
APPLICATION NUMBER: | ANDA203586 |
Other LAMIVUDINE Pharmaceutical Manufacturers / Labelers: